Semaglutides effects can vary from person to person, but understanding what to expect can help you set realistic expectations
By taking these steps, you can ensure that you are using semaglutide safely and effectively, minimizing potential risks, and maintaining your health
A few bites of chicken and rice
Based on the current stage of clinical development and estimated trial completion dates registered on ClinicalTrials.gov, a realistic earliest possible timeline might be considered as follows: 20252026: Completion of key phase 3 TRIUMPH trial data 20262027: Potential regulatory submission to the MHRA (and FDA/EMA in parallel) 20272028: Possible MHRA marketing authorisation, subject to satisfactory review 2028 onwards: NICE technology appraisal and potential NHS commissioning decision These timelines are speculative and depend on multiple variables, including trial outcomes, the completeness of the regulatory submission, MHRA review timelines, and NICE deliberations
50,51 Pharmacokinetics of GLP-1 RAs and a Dual GLP-1/GIP RA Numerous studies have reported the pharmacokinetics of these drugs, with each study showing varying pharmacokinetic parameters based on differences in the clinical study design, pharmacokinetic parameter calculation approaches, or analytical methods
Semaglutide mimics GLP-1, a hormone that regulates appetite and blood sugar